ORG
CSL Seqirus Secures Fourth US Award to Enhance Bird Flu Vaccine Stockpile
CSL Seqirus, bird flu vaccine, US government award, BARDA, pandemic preparedness, avian influenza, H5N1, vaccine stockpile, public health protection
Gilead’s Trodelvy Fails to Meet Primary Endpoint in Lung Cancer Trial, but Shows Promise in Subgroup Analysis ###
Gilead Sciences, Trodelvy, Lung Cancer, ASCO, FDA, Clinical Trials, Oncology, Immunotherapy, Trop-2 Directed Antibody-Drug Conjugate
Novartis’ Scemblix Demonstrates Superior Efficacy and Safety in Newly Diagnosed Leukemia Patients ###
Novartis, Scemblix, Leukemia, Chronic Myeloid Leukemia (CML), Tyrosine Kinase Inhibitors (TKIs), Gleevec, American Society of Clinical Oncology (ASCO)
Biogen and Ionis’ ALS Treatment Qalsody Receives European Commission Approval
Biogen, Ionis, Qalsody, ALS, European Commission, Marketing Authorization, Rare Disease, SOD1-ALS, Neurofilament, Clinical Trials
Ultragenyx Advances Gene Therapy for Glycogen Storage Disease Type Ia Following Phase 3 Success
Ultragenyx, gene therapy, glycogen storage disease type Ia, DTX401, Phase 3 study, GlucoGene, rare genetic diseases
Galapagos Partners with Adaptimmune for $665M T-Cell Therapy Collaboration
Galapagos, Adaptimmune, T-cell therapy, MAGE-A4 TCR, Uza-cel, Biobucks collaboration, Licensing deal, Financing, Next-generation therapy
FDA Delays Dupixent Decision for Uncontrolled COPD Treatment, EU Panel Recommends Approval
Dupixent, dupilumab, COPD, FDA, EU approval, Sanofi, Regeneron, uncontrolled COPD, treatment delay
Early Detection and Personalized Treatment of Colorectal Cancer: The Promise of Whole Genome Sequencing-Based Circulating Tumor DNA Tracking” ###
Circulating tumor DNA (ctDNA), Whole genome sequencing (WGS), Colorectal cancer, Early detection, Personalized treatment, Adjuvant therapy, Molecular residual disease (MRD), Liquid biopsies
FDA Delays Dupixent Decision for COPD by Three Months, EMA Recommends Approval
FDA, Dupixent, COPD, EMA, Regeneron, Sanofi, Priority Review, PDUFA, Boreas, Notus, Phase III Trials
Eli Lilly Invests $5.3 Billion in Indiana Plant to Boost Diabetes and Obesity Drug Production ###
Eli Lilly, Diabetes, Obesity, Mounjaro, Zepbound, Tirzepatide, Indiana, Manufacturing, API, Novo Nordisk, GLP-1 drugs